Lancet Editorial + medRxiv Preprint: Generic Semaglutide Production Cost $28-140/Person-Year, Could Reach 84% of Global Obesity Burden by End-2026
The Lancet's 'Making Treatment for Obesity More Equitable' editorial (March 2026) and an accompanying medRxiv preprint (Hill et al., March 4, 2026) synthesized 2024-2025 active pharmaceutical ingredient shipment data to estimate generic semaglutide production costs at $28-140/person-year for injectable formulations and $186-380/person-year for oral formulations. By the end of 2026, generic injectable semaglutide could be available in 160 countries covering 69% of global T2DM and 84% of clinical obesity. The 10 countries where Novo Nordisk's 2026 patents expired represent 44% of the global population and 48% of the global obesity burden — including Brazil, Canada, China, India, and Turkey. The constraint isn't manufacturing economics; it's device-patent thickets (57% of analyzed semaglutide patents are device patents) and policy coordination (pooled procurement, voluntary licensing, tiered pricing).